Related Experiment Video
Updated: Oct 15, 2025
07:24
Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
Published on: April 8, 2013
24.4K
SGLT2 inhibitors in heart failure with reduced ejection fraction
Uday Sankar Das1, Aritra Paul2, Suvro Banerjee3
1Apollo Gleneagles Hospitals, Kolkata, India.
Summary
Sodium-glucose co-transporter 2 (SGLT2) inhibitors offer significant benefits beyond blood glucose control. These drugs effectively reduce cardiovascular events and slow renal failure progression, even in non-diabetic patients with heart conditions.
Area of Science:
- Cardiology
- Nephrology
- Endocrinology
Background:
- Sodium-glucose co-transporter 2 (SGLT2) inhibitors lower blood glucose by blocking glucose reabsorption in renal tubules.
- Initial trials revealed SGLT2 inhibitors reduce cardiovascular events and renal failure in high-risk patients.
- Emerging evidence supports SGLT2 inhibitors for heart failure treatment and renal protection, irrespective of diabetes status.
Purpose of the Study:
- To review clinical trial data on SGLT2 inhibitors for heart failure with reduced ejection fraction.
- To examine the role of SGLT2 inhibitors in preventing heart failure in high-risk diabetic patients.
- To discuss potential mechanisms behind the cardiovascular benefits of SGLT2 inhibitors.
Main Methods:
- Review of major clinical trials including EMPA-REG OUTCOME, DECLARE-TIMI 58, CANVAS, VERTIS-CV, DAPA-HF, and EMPEROR-REDUCED.
- Analysis of evidence for SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin, ertugliflozin) in cardiovascular and renal outcomes.
- Discussion of proposed mechanisms for SGLT2 inhibitors' cardioprotective effects.
Main Results:
- SGLT2 inhibitors demonstrated reduced hospitalizations for cardiovascular disease in high-risk populations.
- Dapagliflozin and empagliflozin showed efficacy in treating heart failure, with or without diabetes.
- These agents offer a novel therapeutic option for patients with comorbid diabetes, heart, and renal disease.
Conclusions:
- SGLT2 inhibitors represent a significant advancement in managing patients with diabetes, heart failure, and renal disease.
- Their cardiovascular and renal protective mechanisms, particularly in heart failure, warrant further investigation.
- SGLT2 inhibitors provide a new therapeutic avenue for cardiovascular and renal protection.
Related Concept Videos
01:30Heart Failure V: Medical Management
49
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
49
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
569
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
569
01:26Heart Failure Drugs: Inotropic Agents
826
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
826
01:22Heart Failure Drugs: Diuretics
529
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
529
01:22Heart Failure VI: Adjunct Therapies
53
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
53
01:22Heart Failure Drugs: β-Blockers
481
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
481